ARYA Atherosclerosis最新文献

Background: In this study, we aimed to investigate the prognostic implications of lead aVR ST-segment elevation in an initial electrocardiogram (ECG) in patients diagnosed with acute coronary syndrome (ACS). Furthermore, we evaluated the association between electrocardiographic changes in lead aVR and objective measures such as angiographic findings and Syntax score.

Methods: This retrospective cohort study, conducted as a pilot study, encompassing both a retrospective cross-sectional analysis and a longitudinal follow-up, took place at Chamran Hospital from November 2017 to October 2019. A 6-month follow-up was conducted via phone interviews to assess patient outcomes.

Results: During the study period, there were 76 admissions with the final diagnosis of acute coronary syndrome and lead aVR ST-segment elevation on ECG. ARB intake and the severity of right coronary artery stenosis were significantly higher in patients with STE-aVR ≥1.5 mm. The clinical pathway analysis and 6-month follow-up outcomes concerning ST-segment changes in lead aVR did not reveal statistically significant differences in the distribution of various intervention strategies and clinical events. The overall ST-change was a significant risk factor for 6-month follow-up angiography (OR: 1.10; 95% CI: 1.002 to 1.213) and was also significantly associated with any stenosis in the RCA territory (OR: 1.10; 95% CI: 1.004 to 1.21). There was no significant association between ST-change and other follow-up hospital and angiography outcomes.

Conclusion: The findings suggest that medication history, particularly with angiotensin receptor blockers, may shape the observed ST-segment changes in lead aVR. However, further investigation is needed to better understand the clinical implications of these trends.

Background: Heart failure (HF), or congestive Heart failure (CHF), is a heart disorder with a number of symptoms caused by the heart's inability to pump blood. Our aim in conducting this study is to investigate the adherence to dietary approaches to stop hypertension (DASH) diet components and the risk of HF in Iranian adult women and men.

Methods: In this hospital-based, case-control study, we included 340 participants (194 men and 146 women) aged 30-70 years who were recently (less than 6 months) diagnosed with HF. In this study, there were 169 participants in the control group and 171 participants in the case group. A semi-quantitative food frequency questionnaire (FFQ) with 148 items was used to assess food intake. Multiple logistic regression statistical tests were used to evaluate the relationship between DASH score and HF.

Results: After adjusting for confounding variables, the data showed that adherence to the DASH diet was associated with a reduced risk of HF. Our data show that a significant relationship was found between the consumption of fruits (OR: 0.62; 95% CI: 0.53-0.68), vegetables (OR: 0.53; 95% CI: 0.28-0.81), legumes and nuts (OR: 0.75; 95% CI: 0.65-0.68), and heart failure, but no significant relationship was found with the other components of the DASH diet and heart failure.

Conclusion: Findings suggest that there is an inverse relationship between adherence to the DASH-style diet and the likelihood of HF, and adherence to some components of the DASH diet was also effective in reducing the risk of HF. To obtain more complete results, it is necessary to conduct cohort studies and randomized clinical trials.

Background: Although several studies have attempted to identify coronary artery disease (CAD) risk factors, few have explored the association between lifestyle-related factors and the severity of coronary artery stenosis. The present study was designed to assess the association between a combination of lifestyle, dietary, cardiometabolic, psychological, and mental factors, and CAD severity in adults undergoing angiography.

Methods: This cross-sectional study aimed to recruit a total of 700 patients (aged 35 to 75 years) who met the inclusion criteria and were referred for angiography between July 2020 and November 2021 to Afshar Hospital, a central heart disease hospital in Yazd city, Iran. To assess the presence and intensity of CAD, we used the Gensini and SYNTAX scores. Biochemical factors were measured using standard kits from serum samples, and extra serum and whole blood samples were retained for further analyses. Data on general information, dietary food and supplement intake, eating habits, medicinal herbs consumption, psychological and mental state, sleep quality, and other variables were gathered by trained interviewers using specific questionnaires.

Results: In total, 720 participants (444 males and 276 females) aged 56.57±9.78 years were included in the current study. Moderate to severe coronary artery stenosis was prevalent in 47.0% and 17.9% of participants based on Gensini and SYNTAX scores, respectively.

Conclusion: The results of this study will enhance our understanding of the association between different risk factors and the severity of coronary artery stenosis.

Background: The effectiveness of cardiac rehabilitation (CR) programs following either percutaneous coronary intervention (PCI) or coronary artery bypass grafting (CABG) has been separately studied. Few studies have compared the effects of similar CR programs between PCI and CABG. This study aimed to compare the effects of CR in patients recruited following either PCI or CABG on coronary heart disease risk factors, psychological variables, and functional capacity.

Methods: For this retrospective study, the documents of the CR program registry of the Isfahan Cardiovascular Research Institute were reviewed from 2008 to 2021. Patients with ischemic heart disease undergoing PCI or CABG were enrolled in an 8-week exercise-based cardiac rehabilitation program. Demographics, smoking status, clinical data, echocardiographic parameters, laboratory data, functional capacity, and psychological status were assessed.

Results: Patients who underwent CABG (n=557) were more likely to be referred to CR than those who underwent PCI (n=440). All variables changed significantly after the CR program compared to their baseline value in both the PCI and CABG groups. However, low-density lipoprotein and total cholesterol levels, peak systolic blood pressure, and resting and peak diastolic blood pressure did not change in any of the groups, and fasting blood sugar (p=0.01) and triglyceride (TG) (p=0.01) levels significantly decreased only in the PCI group. Between-group comparisons indicated that after adjustment, no significant difference was observed between the PCI and CABG groups except for TG, which was significantly reduced in the PCI group (p=0.01).

Conclusion: The CR program was equally effective in patients who underwent either PCI or CABG.

Carotid atherosclerosis disease assessment can predict the patient's risk of cardiovascular disease (CVD). The purpose of this review is to provide a comprehensive review of carotid atherosclerosis disease's pathophysiology, diagnostic evaluation, imaging applications, and treatment strategies. Carotid atherosclerosis is diagnosed using a variety of techniques, including transcranial Doppler imaging (TCD), computed tomography angiography (CTA), magnetic resonance angiography (MRA), and cerebral digital subtraction angiography (DSA), with duplex ultrasound (DUS) as the primary screening. Measurements of carotid intima-media thickness (CIMT) have drawn attention recently as a marker of early-stage carotid atherosclerosis or CVD risk prediction. The classification of cardiovascular risk may be enhanced by the expanding fields of stress testing and carotid plaque screening.

Background: Cerebral ischemia or stroke is the second leading cause of death in the world, and most surviving patients suffer from long-term physical and cognitive disabilities, which create many social and economic problems for them and society. Visual attention impairment is a common cognitive complication among patients with cerebral ischemia, especially in the Middle Cerebral Artery (MCA). One way to improve attention in these patients is cognitive rehabilitation. RehaCom software is one of the computer-based tools to rehabilitate visual attention in these patients. The purpose of this study was to evaluate RehaCom cognitive rehabilitation on different aspects of visual attention in patients with middle cerebral artery ischemia.

Methods: In this single-blind randomized clinical trial, 30 patients with cerebral ischemia in MCA territories were selected and randomly divided into control (n=15) and intervention (n=15) groups. Visual attention of both groups was assessed before the treatments using the Integrated Visual-Auditory test (IVA). Then the intervention group was rehabilitated for 8 sessions of 45 minutes each with RehaCom cognitive software, according to our selected modules, while the control group was only under intervention by non-targeted computer games. After applying the treatments, visual attention in the two groups was assessed using the IVA test.

Results: There were no significant differences in visual focus attention between the intervention and control groups before the intervention (29.20±30.06 and 49.53±29.69, P value >0.05). In addition, there were no significant differences in visual selective attention in both groups before the study (23.07±24.73, 39.27±27.08, P value >0.05). However, significant differences were found in visual sustained attention, visual alternating attention, and visual divided attention at baseline (P value <0.05). After the intervention, visual focus attention in the intervention group was significantly higher than in the control group (84.67±26.51, 57.20±31.44, P value <0.05). RehaCom cognitive software intervention increased visual divided attention in the intervention group (88.40±14.85 versus 72.70±25.73, P value <0.05).

Conclusion: These results demonstrate that using RehaCom cognitive software can improve focus attention and visual attention in the intervention group. Cognitive rehabilitation with RehaCom was able to improve visual attention deficits in patients with middle cerebral artery ischemia.

Introduction: Primary percutaneous coronary intervention (PPCI) is the gold standard approach to restore blood flow in ST-segment elevation myocardial infarction (STEMI); however, the no-reflow phenomenon as a potential complication of PPCI can worsen the outcomes. It has been hypothesized that adjunctive prophylactic intracoronary infusion of low-dose fibrinolytic might improve the PPCI outcomes; however, this theory is a matter of debate. The current study aims to investigate the value of adjunctive prophylactic intracoronary low-dose alteplase to prevent the no-reflow phenomenon in patients with STEMI.

Method: This case-control study was conducted on 80 STEMI patients who underwent PPCI. The patients were assigned into the case group who were intervened by 10 mg adjunctive intracoronary alteplase immediately at the end of the balloon angioplasty (n=40) and controls (n=40) who underwent conventional PPCI only. The angioplasty-associated outcomes including final TIMI score, need for no-reflow treatment, ST-segment resolution, post-PPCI complications, and death were compared between the groups.

Results: Alteplase use was accompanied by significantly improved final TIMI flow scores (P-value<0.001) and fewer requirements for no-reflow treatments (P-value<0.001); however, it did not improve the ST-segment resolution (P-value=0.491). The mortality rate and post-angioplasty complications did not differ between the groups (P-value>0.05).

Conclusion: Based on the findings of this study, adjunctive infusion of low-dose intracoronary alteplase during PPCI could not efficiently prevent the no-reflow phenomenon. Although the final TIMI flow and need for post-stenting no-reflow treatment improved, ST-segment resolution did not occur dramatically. Given that, this approach requires further investigations and should be considered cautiously.

Introduction: In recent years, transradial cardiac catheterization has become the preferred method. However, it can result in a significant complication known as radial artery occlusion (RAO). The medical management of RAO remains controversial, especially with the emergence of novel oral anticoagulants. Nevertheless, there is limited data on the use of these agents for treating RAO, which is the focus of this study using apixaban.

Method: This pilot double-blinded randomized clinical trial involved 30 patients who developed RAO following transradial coronary angiography. The patients were randomly assigned to receive either apixaban (2.5 mg twice daily) or a conservative approach for 30 days. Doppler ultrasonography was performed at baseline and at the end of the intervention to assess radial artery diameter and the resolution of arterial patency. Demographic, medical, medication, and clinical characteristics were collected.

Results: The mean age of the studied population was 59.43±12.14 years, and the majority were males (60%). Radial artery resolution was observed in 21 (70%) patients, independent of medication use. There was no significant association between resolution and age (P-value=0.62), gender (P-value=0.74), body mass index (P-value=0.23), smoking (P-value=0.64), diabetes (P-value=0.999), hypertension (P-value=0.74), statins (P-value=0.999), antiplatelet therapy (P-value=0.999), length of angiography (P-value=0.216), or follow-up arterial diameter (P-value=0.304). Recanalization occurred in 13 (86.7%) cases in the apixaban treatment group, compared to 8 (53.3%) individuals in the control group, indicating a significant difference (P-value=0.046).

Conclusion: The study findings suggest no demographic, medical, medication, or clinical factors were associated with arterial recanalization. However, a one-month treatment with apixaban at a dose of 2.5 mg twice daily appeared to be effective.

Introduction: The generation of reactive oxygen species, which is induced by the activation of the xanthine oxidase (XO) enzymatic system, is one of the primary causes of ischemia-reperfusion injury for an ischemic heart. Allopurinol, as an XO inhibitor, plays an inhibitory role in free radical production in ST-elevation myocardial infarction (STEMI) patients. The aim of this study is to evaluate the impact of allopurinol pre-treatment on post-revascularization outcomes in patients admitted with STEMI.

Method: Ninety patients with acute STEMI were enrolled in this randomized double-blind clinical trial and divided into two equal groups. The allopurinol group received a 600 mg allopurinol loading dose before the emergency PCI, and the control group received a placebo medication of the same shape. Thrombolysis in Myocardial Infarction (TIMI) flow, ECG changes, troponin level, and the occurrence of major cardiac events (MACE) during a 1-month follow-up were assessed.

Results: In the end, 81 patients were analyzed. The mean age of the patients was 59.52(11.31) and 61.3(9.25) in the allopurinol and control groups, respectively (p = 0.49). The troponin level 48 hours after the PCI and ST-elevation regression showed no significant difference between the groups [(p = 0.25) and (p = 0.21), respectively]. TIMI flow had improved in the allopurinol group compared to the placebo (p = 0.02). The PCI success rate was 78.6% and 61.5% in the case and control groups, respectively (p = 0.09). MACE and other clinical outcomes were similar between the groups (p > 0.05).

Conclusion: This study revealed that allopurinol pre-treatment could improve TIMI flow in patients undergoing primary or rescue PCI in an acute STEMI setting.

Introduction: The prevention and control of dyslipidemia, as an important risk factor for cardiovascular diseases (CVDs), is a priority for the healthcare system to reduce the burden of these diseases. The purpose of this protocol is to outline the key steps of the first Iranian Dyslipidemia Clinical Practice Guideline development, which can be used by other researchers as a guide to design a standard, comprehensive, evidence-based, and local context-based guideline.

Method: This guideline will be developed and reported according to the format of the World Health Organization (WHO) Handbook for Guideline Development. All members of the guideline development team will sign the declaration-of-competing-interests (DOI) forms. The development of the authors' guideline will be supported by five groups: the steering committee (SC), the Guideline Developing Group (GDG), the systematic review (evidence synthesis) group, and the external review group. The authors will also establish a patient advisory group to inform guideline development by patients' values and preferences. The SC and GDG will determine the scope of the guideline and will design PICO questions. The systematic review group will systematically search Embase, PubMed, Scopus, Web of Sciences, Cochrane Library, and Google Scholar from inception. The systematic review group will assess the risk of bias and create evidence summaries using the Grading of Recommendations Assessment, Development, and Evaluation (GRADE) system. The recommendations of this guideline will be divided into strong recommendations and weak or conditional recommendations or suggestions.

Conclusion: This clinical practice guideline will provide clinicians and healthcare professionals with new evidence-based recommendations for the diagnosis, management, and treatment of dyslipidemia in children and adults.